Comparative Pharmacology
Head-to-head clinical analysis: METHADONE MOUD versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADONE MOUD versus WESTADONE.
Methadone (MOUD) vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist with high affinity. It also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and maintenance effects.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
Initial: 20-30 mg orally once daily, titrated to effect. Maintenance: 10-120 mg orally once daily. Route: oral (tablet, liquid). Frequency: once daily.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours following single dose; 13-50 hours with chronic dosing (due to tissue redistribution). Context: prolonged half-life supports once-daily dosing for opioid use disorder but requires careful titration to avoid accumulation.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Primarily renal (20-40% as unchanged drug, with urine pH-dependent elimination; 50% as metabolites including EDDP and EMDP). Biliary/fecal excretion accounts for approximately 10-15%.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category A/B
Category C
Opioid Agonist
Opioid Agonist